Research article summary (published 4 Oct 2009):

Can treating the SYK cell cure leukemia?

Full Abstract

Targeted therapy has remained elusive for most acute myeloid leukemia patients. In this issue of Cancer Cell, Stegmaier and colleagues identify SYK as a key mediator of the differentiation block seen in this disease. Their data suggest that SYK inhibition may be an effective therapy for a significant proportion of AMLs.

Author information

Author/s: Downing, James R (JR);

Affiliation: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. james.downing(-atsign-)stjude.org

Journal and publication information

Publication Type: Comment; Journal Article

Journal: Cancer cell (Cancer Cell), published in United States. (Language: eng)

Reference: 2009-Oct; vol 16 (issue 4) : pp 270-1

Dates: Created 2009/10/05; Completed 2009/10/15;

PMID: 19800569, status: MEDLINE (last retrieval date: 10/15/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

Comments and Corrections

CommentOn: Cancer Cell. 2009 Oct 6;16(4):281-94. (PMID: 19800574)

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Animals Antineoplastic Agents - pharmacology Cell Differentiation - drug effects Cell Proliferation - drug effects Dose-Response Relationship, Drug Gene Expression Regulation, Leukemic Genomics - methods Humans Inhibitory Concentration 50 Intracellular Signaling Peptides and Proteins - antagonists & inhibitors; genetics; metabolism

Leukemia, Myeloid, Acute - drug therapy; genetics; metabolism; pathology Oxazines - pharmacology Phosphorylation Protein Kinase Inhibitors - pharmacology Protein-Tyrosine Kinases - antagonists & inhibitors; genetics; metabolism Proteomics - methods Pyridines - pharmacology Quinazolines - pharmacology Time Factors Tyrosine

Associated Chemicals: Antineoplastic Agents (0) ; Intracellular Signaling Peptides and Proteins (0) ; Oxazines (0) ; Protein Kinase Inhibitors (0) ; Pyridines (0) ; Quinazolines (0) ; R788 compound (0) ; gefitinib (184475-35-2) ; Tyrosine (55520-40-6) ; Protein-Tyrosine Kinases (EC 2.7.1.112) ; Syk kinase (EC 2.7.1.112)

Related articles

These are the highest related articles currently in the database:

• Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates. 13 Aug 2008
• Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay. 29 Nov 2007
• Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. 29 Apr 2008
• Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. 25 Nov 2006
• Expression and role of DJ-1 in leukemia. 19 Aug 2008
• A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. 30 Jan 2006
• Cellular targets of gefitinib. 13 Jan 2005
• Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. 25 Sep 2008
• Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. 6 Oct 2004
• Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. 30 Mar 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.